X4 Pharmaceuticals (NASDAQ:XFOR) Chairman Buys 4,600 Shares of Stock

Key Points

• Chairman Adam Craig purchased 4,600 X4 Pharmaceuticals shares at an average price of $2.58, increasing his direct ownership by 1.40% to 333,251 shares.
• XFOR shares rose 6.2% to $2.75, though the stock remains near its 52-week low and below its 50-day and 200-day moving averages.
• Analysts hold a “Moderate Buy” consensus with an average price target of $11.25, while the company recently beat quarterly EPS and revenue expectations despite continuing losses.

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) Chairman Adam Craig purchased 4,600 shares of the company's stock in a transaction that occurred on Friday, October 16th. The stock was acquired at an average cost of $2.58 per share, with a total value of $11,868.00. Following the purchase, the chairman directly owned 333,251 shares of the company's stock, valued at $859,787.58. This trade represents a 1.40% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

X4 Pharmaceuticals Trading Up 6.2%

NASDAQ:XFOR traded up $0.16 during trading hours on Monday, hitting $2.75. The company had a trading volume of 602,984 shares, compared to its average volume of 638,974. The company has a market capitalization of $272.66 million, a PE ratio of -2.29 and a beta of 0.46. The stock has a 50-day moving average price of $3.53 and a 200 day moving average price of $3.88. X4 Pharmaceuticals, Inc. has a 52 week low of $2.43 and a 52 week high of $4.83. The company has a debt-to-equity ratio of 0.49, a current ratio of 11.30 and a quick ratio of 11.02.

X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.18) by $0.05. X4 Pharmaceuticals had a negative net margin of 568.80% and a negative return on equity of 63.05%. The business had revenue of $8.81 million for the quarter, compared to the consensus estimate of $2.42 million. On average, equities research analysts predict that X4 Pharmaceuticals, Inc. will post -0.67 EPS for the current fiscal year.

Institutional Investors Weigh In On X4 Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Pettinga Financial Advisors LLC bought a new position in shares of X4 Pharmaceuticals during the 2nd quarter valued at approximately $47,000. SummitTX Capital L.P. purchased a new position in X4 Pharmaceuticals in the first quarter worth about $46,000. WINTON GROUP Ltd increased its stake in X4 Pharmaceuticals by 35.8% during the second quarter. WINTON GROUP Ltd now owns 14,400 shares of the company's stock worth $67,000 after acquiring an additional 3,800 shares during the last quarter. AXQ Capital LP bought a new stake in X4 Pharmaceuticals during the second quarter worth approximately $107,000. Finally, Wellington Management Group LLP purchased a new stake in X4 Pharmaceuticals during the second quarter valued at approximately $242,000. 72.03% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

XFOR has been the topic of several research analyst reports. Wells Fargo & Company started coverage on shares of X4 Pharmaceuticals in a research report on Friday, July 10th. They set an "overweight" rating and a $11.00 price target on the stock. Weiss Ratings upgraded X4 Pharmaceuticals from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, October 2nd. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $11.25.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases caused by immune and hematologic dysfunction. The company's research centers on the CXCR4 biological pathway, which regulates the movement and retention of certain immune cells in the bone marrow and other tissues.

X4's primary product is XOLREMDI (mavorixafor), an oral CXCR4 antagonist approved by the U.S. Food and Drug Administration in 2024 for use in people aged 12 and older with WHIM syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.